Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial
Sign Up to like & getrecommendations! Published in 2021 at "Diabetologia"
DOI: 10.1007/s00125-021-05407-5
Abstract: In previous work, we reported the HR for the risk (95% CI) of the secondary kidney composite endpoint (time to first event of doubling of serum creatinine from baseline, renal dialysis/transplant or renal death) with… read more here.
Keywords: creatinine; vertis trial; type diabetes; diabetes mellitus ... See more keywords
Evaluation of cardiovascular and renal outcomes with ertugliflozin: what is the VERdict from the VERTIS-CV trial?
Sign Up to like & getrecommendations! Published in 2020 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2020.1822327
Abstract: ABSTRACT Introduction A growing number of antidiabetic agents have demonstrated cardiovascular and renal benefits in cardiovascular outcome trials (CVOTs), despite such trials being principally required to rule out excess cardiovascular risk. Areas covered This article… read more here.
Keywords: trial; vertis trial; renal outcomes; cardiovascular renal ... See more keywords
Interpreting the results of the VERTIS‐CV trial: Is this the end of the “class effect” perspective?
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Diabetes"
DOI: 10.1111/1753-0407.13105
Abstract: Division of Endocrinology and Metabolism and Diabetes Center, First Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA University Hospital, Thessaloniki, Greece Diabetes Center, Second Department of Internal Medicine, Democritus University of Thrace,… read more here.
Keywords: medicine; vertis trial; results vertis; trial end ... See more keywords